Clinical Trials Logo

Heart Failure With Normal Ejection Fraction clinical trials

View clinical trials related to Heart Failure With Normal Ejection Fraction.

Filter by:

NCT ID: NCT03871803 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

β-blockers Withdrawal in Patients With HFpEF and Chronotropic Incompetence: Effect on Functional Capacity (Preserve-HR)

Preserve-HR
Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

The pathophysiology of heart failure with preserved ejection fraction (HFpEF) is complex and multifactorial. Chronotropic incompetence has emerged as a crucial mechanism, particularly in elderly patients. Betablockers, drugs with negative chronotropic effect, are commonly used in HFpEF, despite current evidence does not support its routine use in these patients. The aim of this work is to evaluate the effect of betablockers withdrawal in patients with HFpEF and chronotropic incompetence on functional capacity assessed by the peak oxygen consumption at maximal exercise (peakVO2) at 15 and 30 days after the intervention

NCT ID: NCT03833336 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)

PREFER-HF
Start date: August 23, 2017
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate whether the administration of iron to patients with heart failure and preserved ejection fraction results in an improvement of symptoms and functional class, in addition to evaluating whether oral iron is equivalent to intravenous iron to achieve this improvement.

NCT ID: NCT03787082 Not yet recruiting - Clinical trials for Pulmonary Hypertension

Chlorhexidine Mouthwash and Oral Nitrate in Adults With Pulmonary Hypertension

Start date: May 2019
Phase: Phase 1
Study type: Interventional

This is an open-label, single-center study to examine distinguishing features of the structure and function of the oral and gut microbiome in volunteers with PH in the breakdown of oral nitrate and effect on hemodynamics.

NCT ID: NCT03775577 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Exercise Intolerance in Heart Failure

Start date: April 1, 2017
Phase:
Study type: Observational

The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.

NCT ID: NCT03751748 Not yet recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Flow Regulation by Opening the Septum in Patients With Heart Failure Trial

FROST-HF
Start date: January 1, 2019
Phase: N/A
Study type: Interventional

To investigate the safety and efficacy of a novel atrial flow regulator (AFR) device in patients with heart failure and preserved ejection fraction.

NCT ID: NCT03672591 Not yet recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Renal Hemodynamics in Patients With HFpEF

Start date: November 30, 2018
Phase:
Study type: Observational

Impaired renal function and heart failure with preserved ejection fraction (HFpEF) are two often co-existing medical conditions and are known to be associated with adverse cardiovascular outcome and increased mortality. The relationship between HFpEF and renal impairment is bidirectional. On the one hand, renal dysfunction has been shown to be an independent risk factor for the development of HFpEF. On the other hand, an increase in central venous pressure leading to renal dysfunction by a reduction of renal blood flow (RBF) and perfusion pressure (RPP) as well as activation of the renin-angiotensin-aldosterone system (RAAS) in patients with HFpEF has been previously described. In the literature, several studies aimed to investigate the association between renal (dys-) function and HFpEF. In all these studies, renal function was assessed by determination of standard kidney function parameters such as serum creatinine, eGFR and urinary albumin to creatinine ratio (UACR). Constant infusion input clearance technique however offers a more detailed evaluation of renal function and hemodynamics. To the best of knowledge, renal hemodynamics in patients with HFpEF have not yet been investigated by clearance technique. Therefore, the aim of the present study is to evaluate renal function and hemodynamics by means of constant infusion input clearance technique with sodium p-aminohippuric acid (PAH) and Iohexol in 40 patients with HFpEF. The constant infusion input clearance technique offers an exact evaluation of renal function by measuring (not estimating) glomerular filtration rate and renal hemodynamic parameters such as renal plasma flow (RPF), filtration fraction (FF) and intraglomerular pressure (IGP). These results will be compared to 140 subjects without HFpEF that have participated in various studies and have been analyzed with the same constant infusion input clearance technique performed in the Clinical Research Center of the University Hospital Erlangen-Nuremberg. Additionally, flow mediated vasodilation (FMD), pulse wave velocity and parameters of retinal vascular remodeling by means of scanning laser Doppler flowmetry (SLDF) will be assessed in patients with HFpEF thereby allowing to examine the relationship between vascular remodeling in the systemic and renal circulation.

NCT ID: NCT03624010 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Start date: November 14, 2018
Phase: Phase 2
Study type: Interventional

PH-HFpEF patients will receive weekly open-label doses of levosimendan and be periodically evaluated for safety and effectiveness in extended use.

NCT ID: NCT03620526 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Inhaled Iloprost and Exercise Hemodynamics and Ventricular Performance in Heart Failure With Preserved Ejection Fraction

ILO-HOPE
Start date: November 29, 2017
Phase: Phase 4
Study type: Interventional

BACKGROUND There is no effective medical treatment for heart failure with preserved ejection fraction (HFpEF). Increases in pulmonary capillary wedge pressure (PCWP) develop in patients with HFpEF. Prostacyclin analogo can possible reduced PA pressure along with PWCP pressure, as with exercise. OBJECTIVES This study try to determine whether inhlalation of iloprost improves exercise hemodynamics and cardiac reserve in HFpEF. METHODS In a double-blind, randomized, placebo-controlled, parallel-group trial, subjects with HFpEF underwent invasive cardiac catheterization with simultaneous expired gas analysis at rest and during exercise, before and 15 min after treatment with either inhaled iloprost or matching placebo.

NCT ID: NCT03549559 Not yet recruiting - Diabetes Clinical Trials

Imaging Histone Deacetylase in the Heart

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.

NCT ID: NCT03541603 Recruiting - Clinical trials for Heart Failure With Normal Ejection Fraction

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

HELP
Start date: November 14, 2018
Phase: Phase 2
Study type: Interventional

Phase 2 study to evaluate the efficacy and safety of intermittent levosimendan compared with placebo in hemodynamic improvement with exercise in PH-HFpEF subjects